CSP is considered a prime target for malaria vaccines because it is the first antigen encountered by the host immune system upon infection. By targeting CSP, vaccines can potentially prevent the parasite from successfully invading liver cells, thereby halting the infection at an early stage. The RTS,S/AS01 vaccine, also known as Mosquirix, is one of the most advanced malaria vaccines and specifically targets CSP.
